Multidrug- and Extensively Drug-Resistant Mycobacterium tuberculosis Beijing Clades, Ukraine, 2015.
Adult
Antitubercular Agents
/ pharmacology
Contact Tracing
Drug Resistance, Multiple, Bacterial
/ genetics
Extensively Drug-Resistant Tuberculosis
/ drug therapy
Female
Humans
Male
Middle Aged
Mycobacterium tuberculosis
/ drug effects
Tuberculosis, Multidrug-Resistant
/ drug therapy
Tuberculosis, Pulmonary
/ drug therapy
Ukraine
/ epidemiology
Urban Population
Beijing lineage
MDR TB
Mycobacterium tuberculosis
Ukraine
XDR TB
antimicrobial resistance
contact tracing
drug resistance
tuberculosis
tuberculosis and other mycobacteria
whole-genome sequencing
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
entrez:
25
2
2020
pubmed:
25
2
2020
medline:
16
3
2021
Statut:
ppublish
Résumé
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) is an emerging threat to TB control in Ukraine, a country with the third highest XDR TB burden globally. We used whole-genome sequencing of a convenience sample to identify bacterial genetic and patient-related factors associated with MDR/XDR TB in this country. MDR/XDR TB was associated with 3 distinct Mycobacterium tuberculosis complex lineage 2 (Beijing) clades, Europe/Russia W148 outbreak, Central Asia outbreak, and Ukraine outbreak, which comprised 68.9% of all MDR/XDR TB strains from southern Ukraine. MDR/XDR TB was also associated with previous treatment for TB and urban residence. The circulation of Beijing outbreak strains harboring broad drug resistance, coupled with constraints in drug supply and limited availability of phenotypic drug susceptibility testing, needs to be considered when new TB management strategies are implemented in Ukraine.
Identifiants
pubmed: 32091369
doi: 10.3201/eid2603.190525
pmc: PMC7045844
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-490Références
Int J Tuberc Lung Dis. 2018 Feb 1;22(2):197-205
pubmed: 29506617
Pathogens. 2019 Jun 10;8(2):
pubmed: 31185670
Lancet Infect Dis. 2013 Feb;13(2):137-46
pubmed: 23158499
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031
pubmed: 27685538
Nat Commun. 2014 Sep 01;5:4812
pubmed: 25176035
Nat Genet. 2014 Mar;46(3):279-86
pubmed: 24464101
PLoS Med. 2015 Sep 29;12(9):e1001880
pubmed: 26418737
Nat Genet. 2015 Mar;47(3):242-9
pubmed: 25599400
Thorax. 2017 Sep;72(9):850-852
pubmed: 28209653
Lancet Respir Med. 2015 Dec;3(12):963-72
pubmed: 26597127
J Clin Microbiol. 1991 Nov;29(11):2578-86
pubmed: 1685494
Genome Med. 2015 May 27;7(1):51
pubmed: 26019726
Eur Respir J. 2014 Jul;44(1):23-63
pubmed: 24659544
Nat Genet. 2013 Oct;45(10):1176-82
pubmed: 23995134
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Clin Microbiol Infect. 2019 Aug;25(8):1040.e1-1040.e6
pubmed: 30590114
Lancet Infect Dis. 2018 Apr;18(4):431-440
pubmed: 29326013
Nat Commun. 2015 May 11;6:7119
pubmed: 25960343
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
J Clin Microbiol. 2018 May 25;56(6):
pubmed: 29563202
Eur Respir J. 2015 Apr;45(4):1081-8
pubmed: 25395035
Nat Genet. 2017 Mar;49(3):395-402
pubmed: 28092681
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Tuberculosis (Edinb). 2016 May;98:77-85
pubmed: 27156621
Am J Respir Crit Care Med. 2016 Feb 1;193(3):337-40
pubmed: 26829425
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Clin Microbiol Infect. 2007 Feb;13(2):129-138
pubmed: 17328724
Eur Respir Rev. 2018 Jun 13;27(148):
pubmed: 29898905
Eur Respir J. 2018 Jun 21;51(6):
pubmed: 29748309
J Antimicrob Chemother. 2014 May;69(5):1205-10
pubmed: 24458512